Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study
Read more:
DOI:
10.1007/s10072-021-05489-4
DOI is the universal ID for this study.
This link will take you to the full study.
Abstract:
Background: Oxidative stress is involved in the progression of Parkinson's disease (PD). Recent studies have confirmed that molecular hydrogen (H2) functions as a highly effective antioxidant in animal models of PD. A placebo-controlled, randomized, double-blind, parallel-group clinical pilot study was conducted to assess the efficacy of hydrogen gas inhalation in Japanese patients with PD on treatment with levodopa.
Methods: Twenty participants fulfilling the Movement Disorder Society criteria were enrolled. Participants inhaled 6.5 (0.1) vol% hydrogen gas in 2 L/min of mixed air or placebo air for 16 weeks, twice a day for 1 h.
Results: Five participants were excluded due to deviation from the protocol of the total duration of inhalation 0.05). No adverse events were seen. The compliance to the protocol-based duration of inhalation time in all participants decreased with the elderly participants, the higher daily dose of levodopa, and the higher PDQ-39 items on emotions (n = 20, p < 0.05).
Conclusion: This pilot study revealed that the inhalation of molecular hydrogen gas was safe, but did not show any beneficial effects in patients with PD. Trial registration: UMIN ID: 000,039,217 (October 6, 2018).
| Publish Year | 2021 |
|---|---|
| Country | Japan |
| Rank | Neutral |
| Journal | Neurological Sciences |
| Primary Topic | Brain |
| Secondary Topic | Parkinson's Disease |
| Model | Human |
| Tertiary Topic | Neurodegeneration |
| Vehicle | Gas |
| pH | N/A |
| Application | Inhalation |
| Comparison | |
| Complement | Levodopa |